Stock Market Reviews

Read and share opinions on SCNX (Scienture Holdings, Inc.) stock. Join MyTopStock.com to discover reviews, insights, and discussions from investors about this company's performance in the stock market

Latest News

• SCIENTURE Reports Q3 2025 Financial Results and Provides Business Update
  Nov 13, 2025
• EXCLUSIVE: Scienture Delivers Q3 Revenue Jump With Arbli Sales And Debt Reduction
  Nov 13, 2025
• Scienture Holdings: Q3 Earnings Snapshot
  Nov 12, 2025
• SCIENTURE Announces Addition of Arbli™ (Losartan Potassium) to Formularies of Major National Health Plans
  Nov 4, 2025
• EXCLUSIVE: Scienture Expands Access To Arbli Losartan Oral Suspension With Addition To Formularies Covering 100 Million Lives
  Nov 4, 2025
• SCIENTURE Announces Start of Commercial Sales and Fulfillment of First Orders for Arbli™ (Losartan Potassium)
  Oct 23, 2025
• EXCLUSIVE: Scienture Launches Arbli Oral Suspension, Expanding Options For Hypertension Patients
  Oct 23, 2025
• SCIENTURE’S Arbli™ Becomes First FDA-Approved Ready-to-Use Liquid Losartan Available Through Major U.S. Wholesalers
  Oct 16, 2025
• SCIENTURE Holdings Announces Full Repayment and Conversion of Outstanding Debentures, Strengthening Balance Sheet
  Oct 8, 2025
• SCIENTURE Secures Multiple Commercial GPO Agreements, Expanding U.S. Market Access for Arbli™ (losartan potassium) to more than 2500 Healthcare Institutions
  Oct 1, 2025
• EXCLUSIVE: Scienture Secures Hypertension Drug Purchase Agreements With 2,500 Healthcare Institutions
  Oct 1, 2025
• Scienture Secures Rebate Deal to Promote Stroke and Diabetes Drug Adoption
  Sep 16, 2025
• SCIENTURE Secures PBM-Led GPO Rebate Agreement to Drive Expanded Commercial Coverage and Formulary Access for Arbli™(losartan potassium) in the $256M U.S. Losartan Market
  Sep 16, 2025
• EXCLUSIVE: Scienture Secures PBM-Led Rebate Agreement To Position Hypertension Drug For Rapid Adoption In US Market
  Sep 16, 2025
• Scienture Holdings Second Quarter 2025 Earnings: US$0.47 loss per share (vs US$1.16 loss in 2Q 2024)
  Aug 15, 2025
• Scienture Holdings, Inc. Announces Pricing of $3.9 Million Registered Direct Offering of Common Stock
  Aug 14, 2025
• SCIENTURE announces the shipment of launch quantities of Arbli™ (losartan potassium Oral Suspension) to its 3PL/Distribution Center and receipt of first wholesaler order, marking major commercialization milestones.
  Aug 13, 2025
• Scienture Holdings: Q2 Earnings Snapshot
  Aug 12, 2025
• Scienture Holdings, Inc. Obtains $1.2 Million in Bridge Funding
  Jul 24, 2025